The use of teriparatide in the clinic on patients with cancer is highly improbable as it was shown to increase incidences of osteosarcoma in rodents- but the anti-tumor effects of PTH warrants further investigation into the use of bone anabolic agents against osteolytic breast cancer. Here, PTH is linked to neoplasm.